Commonly reported side effects include: Nausea, vomiting, and diarrhoea particularly during dose escalation Constipation and abdominal discomfort Decreased appetite and early satiety Injection site reactions (mild and transient) Fatigue, especially in the initial weeks of treatment These gastrointestinal effects are consistent with the GLP-1 mechanism and are generally dose-dependent and transient
This multifaceted approach distinguishes Retatrutide from single- or dual-agonist therapies, enabling it to influence multiple physiological pathways that govern appetite, glucose metabolism, and energy expenditure
It also helps to reduce the production of plaque in blood vessels
Each one is preventable if you know what to watch for
Why is Endolift A Great Minimally Invasive Solution
Survodutide vs Retatrutide: Dual vs Triple Agonist Survodutide and retatrutide are both investigational obesity drugs that add glucagon to GLP-1, but retatrutide goes a step further by also targeting GIP